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ABSTRACT 
Objective: Primary CNS sarcomas are very rare tumours with no defined standard of 
care. 
Patients and methods: This study was a retrospective review of seven patients 
diagnosed with a primary CNS sarcoma at neurosurgery department, Mansoura 
university hospital between 2006 and 2018. We reviewed the clinical, radiological, and 
pathological data of these patients. There were 2 female (28.6%) and 5 male (71.4%) 
with age ranged from 8 years to 73 years (mean age 25.4 years). Three patients 
(42.9%) had an intracranial sarcoma, and four (57.1%) had intraspinal tumours. All 
intracranial tumours located in supratentorial region.  
Results: we have characteristic imaging findings inform of osteolytic bony erosion in 
3 patients and marked enhancement of the tumour in 5 (71.4%) patients. We 
operated upon all patients to remove the tumour surgically with our aim is gross 
tumour resection. Tumour was totally resected in 5 patients (71.4%) and subtotal in 
another 2 patients (28.6%). Tumour has dural attachment in 5 cases (71.4%) and brain 
invasion was present in all intracranial 3 patients (42.9%). Postoperative radiotherapy 
was used in 5 patients and postoperative chemotherapy was used in all patients. We 
used immunohistochemical studies for all patients with the most consistent finding 
being strong Desmin positivity. The mean length of patients survival was 4.6 years 
(range from 3 month to 8 years).  
Conclusions: Primary CNS sarcomas are very rare CNS tumours, total surgical 
resection and post-operative radio and chemotherapy provided encouraging 
outcomes. 
 
 
INTRODUCTION  
Primary CNS sarcomas are rare tumours. There are many theories of 
the cell of origin of these tumour. Tumour may arise from pluripotential 
primitive mesenchymal cells which located in the dura, or originated 
from the leptomeningial cells or their extensions via the pia into the 
brain and the spinal cord along the stroma of the choroid plexus, the 
tela choroidea, or the periadventitial spaces and these considered as 
widely accepted theory. 
We can defined sarcomas that have originated from metastases of soft 
tissue or bone sarcomas to the CNS as Secondary CNS sarcomas. These 
tumours result from direct extension of sarcoma located at places 
neighbouring the CNS. 
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PATIENTS AND METHODS 
We looking for all types of primary CNS sarcomas 
between 2006-2018 at Mansoura university hospital 
through retrospective analysis of our CNS tumor 
database which archived in our neurosurgery 
department in these period. The Research Ethical 
committee at Mansoura medical school give us 
permission to use these patients’ data. In this study, 
we defined primary CNS sarcomas as tumours that 
originated primary in the CNS from non-neuronal, 
non-glial, and non-reticular elements, and we not 
include any previously diagnosed benign tumour 
with sarcomatous transformation.  
The medical data of these patients included in 
our definition of a primary CNS sarcoma were then  
analysed for clinical, radiological and pathological 
features.  
All primary CNS sarcoma were investigated for 
any possibility of the presence of extra CNS 
sarcomas at the time of study. The work-up study 
were chest X-ray, chest CT, abdominal and pelvic CT, 
and abdominal ultrasound. 
All cases surgical specimens were examined in 
pathology department by light microscopy using 
eosin and hematoxylin stain, periodic acid-Schiff, and 
reticulin. We used immune histochemical studies in 
all cases.  
The range of follow up varied from 3 month to 8 
years (mean 2.9 years). We calculated the length of 
survival from the date of diagnosis of the disease and 
the end points were the patient death day or the last 
follow-up visit.  
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PATIENT Age/
sex 
location CT M
R
I 
Extent of 
resection 
Radio-
therapy 
Chemo-
therapy 
Dural 
attachment  
Brain 
invasion  
survival 
1 73/f D10 Enhanceme
nt ++, bone 
destruction 
 Total  Yes  Yes  No  No  Alive 1 
years 
then 
absent 
2 8/f D11-12 Enhanceme
nt +++, 
cystic 
 Near total No  Yes  Yes  No  Alive 
1years 
6 
months 
3 8/m Frontal 
lobe 
Enhanceme
nt +++, 
bone 
destruction 
 Total  Yes  Yes  Yes  No  Alive 
8years 
4 47/
m 
Occipital 
lobe 
Cystic, 
enhanceme
nt++,bone 
destruction 
 Total  Yes  Yes  Yes  Yes  
Alive 
3month
s 
5 8/m L2-5 Enhanceme
nt +++, 
bone 
destruction
,cystic 
 Total  No  Yes  No  No  Alive 
7years 
6 18/
m 
Bifrontal 
lobe 
Cystic, 
enhanceme
nt++, 
 Near total Yes  Yes  Yes  Yes  Alive 
7month
s 
7 16/
m 
D4-6 Enhanceme
nt +++, 
bone 
destruction 
 Total  Yes  Yes  Yes  No  Alive 
2years 
 
RESULTS 
Clinical pictures 
We summarized the clinical pictures in this study in 
Table 1. There were 2 female (28.6%) and 5 male 
(71.4%) ranged in age from 8 years to 47 years (mean 
age 19.4 years). Three patients in this study (42.9%) 
were in the first decade of life. Three sarcoma 
patients (42,9%) were intracranial and 4 patients 
(57.1%) were intraspinal. All intracranial sarcomas in 
this series were supratentorial in location, two of 
them presented bilaterally either in frontal or 
occipital lobes. Three of intraspinal tumours (75%) 
were located in the dorsal area and the remaining 
presented in the lumbar region. 
The clinical presentation of these patients varied 
from symptoms and signs of ICP as vomiting, 
headache and papillodema and other presentation 
as focal neurological deficit such as dysphasia, fits, 
hemiparesis for intra cranial tumours and 
paraparesis for the intra spinal tumours. 
 
Radiological features 
We summarized the radiological data in Table 1. CT 
and MRI used for investigation (Fig. 1). CT was 
performed in all patients, tumour enhancement with 
contrast had been obtained. All intracranial tumours 
patients in this study showing osteolytic bony 
destruction. 5 patients (71.4%) showed marked 
humoral enhancement. Magnetic resonance 
imaging in selected cases revealed increased signal 
on T2 images on these lesions, and irregularly 
enhancement after contrast study (Fig. 2). 
 
Surgery 
All patients in these series underwent at least one 
surgical procedure with the aim of surgery is gross 
tumoural resection; only 2 cases underwent another 
surgical operation due to recurrence of the tumour. 
Surgical tumoural resection was total in 5 cases 
(71.4%) and subtotal in the remaining 2 patients 
(28.6%). We performed true cut needle biopsy in just 
a patient of intracranial tumour with extra cranial 
extension prior to surgical excision. Postoperative 
radiotherapy was used in 5 patients (71.4%) and 
postoperative chemotherapeutic agents were used 
in all patients (100%). 
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TABLE 1 showed the operative details of the patients 
included in this series. At surgery, we found dural 
attachment of the tumour in 5 patients (71.4%) and 
parenchymal invasion of the tumour in 2 patients 
(28.6%). We found a well-defined demarcation plane 
of dissection around the lesion in four patients, two 
of them were intracranial sarcoma and the other 
were intra spinal.  
 
Pathological features 
In this series, we found similar histological characters 
of the different intracranial and extra cranial 
sarcomas. We did immunohistochemical studies for 
all cases (Table 2). The most consistent data in 
immunohistochemical studies were strong positive 
results of vimentin and general negative results for 
both neuronal and glial markers. All patients showed 
positive Desmin with more rhabdomyoblastic 
differentiation. 
All patients tumour examined by Electron 
microscopic studies. There are many feature as the 
spindle shape of the cells, lack of well-developed 
junctions, dilated rough endoplasmic reticulum, and 
absence of microvilli and neurosecretory granules. 
The final pathological diagnosis in these series 
was a ewing's sarcoma in 2 (28.6%) patients, a 
embryonal rhabdomyosarcoma in 2 (28.6%), an 
otherwise low grade chodrosarcoma (14.3%), 
synovial sarcoma and an undifferinated sarcoma in 
the remaining three patients alternatively. 
 
Patient 
No 
desmi
n 
neurone 
specific 
enolase 
BDL-2 LCA,CD3,CD9
9 
1 negativ
e positive 
negativ
e NA 
2 negativ
e negative positive NA 
3 positiv
e negative NA NA 
4 negativ
e negative NA negative 
5 negativ
e positive NA NA 
6 NA NA NA NA 
7 positiv
e NA NA negative 
 
Survival 
We calculate the length of survival from the day of 
the diagnosis of the disease (Table 1). We have data 
on survival for 6 patients and lack information in just 
one patient. 
The longest survival time in these study was eight 
years and the shortest survival time was three month 
(mean 3.2 years).  
The durations of patient survival in intracranial 
tumours ranged from three months to eight years 
(mean 2.9 years), while the intraspinal tumours 
ranged from 18 months to 7 years (mean 3.5 years).  
Three months to 8 years (mean 4 years) was the 
length of survival in the cases with gross surgical 
resection of the lesion; and the range of length of 
survival in cases with subtotal tumour resection was 
18 months to 2 years (mean 1, 8 years). 
 
Adjuvant therapy 
We used Postoperative radiation in 5 patients; with a 
radiation dose ranged from 4,500–5,900 Gy.  
On the other hand we used Postoperative 
chemotherapy in all patients. The most used 
chemotherapeutic agents were ifosfamide, 
carboplatin, vincristine and cyclophosphamide. 
 
DISCUSSION 
The occurrence of a primary CNS sarcoma described 
firstly by Bailey in 1929.2 CNS sarcoma with all forms 
considered as rare tumours.⁶⁻¹⁴⁻³ºthe survival in 
sarcoma patients increased than in the past due to 
advances technique in chemotherapy. ⁶⁻²⁶⁻⁴⁵In 
different studies, we found variation in the incidence 
of primary CNS sarcomas which ranged from 0.1% to 
4.3%.³⁻¹⁹⁻²⁷⁻³¹⁻³³⁻³⁶ 
This variation happened due to the term of a 
primary CNS sarcoma were inconsistent in different 
series. Previous reported studies included different 
forms such as giant cell sarcoma, circumscribed 
sarcoma of the posterior fossa, reticulum cell 
sarcoma, and hemangiopericytoma, and this gave a 
false result in high incidence of these tumour 
type.⁷⁻²º⁻²¹⁻²⁵⁻³⁵ In other series, they considered 
cases of primary glial, neuronal, neuroectodermal, 
and/or previously diagnoesd benign meningeal 
tumours with. sarcomatous features as sarcomas 
and this lead to falsely high incidence of these 
tumour type .²³⁻³¹finally, many studies not used 
immunohistochemistry that could be helpful to 
resolve diagnostic issues for many examined 
sarcomatous tumors.²³⁻³³⁻³⁶⁻⁴³ 
The origin of sarcoma have many theories, the 
most accepted theory assumed the origin of these 
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tumour to pluripotential primitive mesenchymal 
cells, the leptomeninges or their extension into the 
brain and the spinal cord via the pia along the. 
periadventitial spaces, the stroma of the choroid 
plexus and the tela choroidea.²⁻⁴⁻¹⁻²⁴⁻²⁵⁻³¹⁻³⁻³⁵⁻⁴⁵  
The causes for occurrence of the primary CNS 
sarcoma is not known yet well accepted inciting 
agent of sarcoma in the literature is radiation 
therapy¹⁹⁻²³⁻²⁷⁻³⁴⁻⁵⁻³⁸⁻⁴⁴. There are another 
predisposing factor as trauma¹⁷⁻¹⁹⁻²⁷⁻²⁸⁻²⁹⁻³¹, genetic 
and familial factors¹⁹⁻³¹ and viruses such as 
RSV.⁸⁻²¹⁻²⁷⁻³¹ 
Primary CNS sarcomas may happen at any life 
decade, with high incidence in children ²³⁻³¹⁻⁴⁴. In 
these series sarcomas were exist in the age range 8–
73 years, with the youngest case was 8 years old. 
Primary intracranial sarcoma clinically presented 
as other intracranial tumours. However, it can 
present with intracranial hemorrhage due to their 
extreme vascularity¹⁻¹⁵⁻²⁷⁻³º. The clinical 
presentation of primary intraspinal sarcoma had the 
same clinical presentation of other intraspinal 
tumours. 
There are nonspecific image of primary CNS 
sarcomas on radiology as CT or MRI. In our series, 
tumour was large and with different heterogeneous 
density, cystic (hypodense), or solid and in one 
patient presented bilaterally in intracranial. Two of 
the 7 tumours had both solid and cystic components.  
MRI of sarcoma was available with an 
inhomogeneous signal. Solid parts of the tumour 
usually enhanced after administration of 
intravenous contrast. Enhancement of the tumour 
after contrast in the MRI has been a feature of 
sarcomas in the many series in literature ³⁴⁻³⁵. An 
important characteristic feature of sarcoma is the 
location near to the surface of the brain or the 
meninges, and it existed in four patients in our 
studies `. CNS sarcoma have high incidence of 
leptomeningeal spread ¹¹⁻¹³⁻⁴⁵. There are many 
differential diagnosis of primary CNS sarcoma on 
radiology as CT and MRI includes glioma, 
medulloblastoma in posterior fossa, cranial and 
spinal meningioma, and ependymoma ¹⁹⁻²⁷⁻³²⁻³⁶. 
In current study, our paients tumor are located in 
supratentorial region with the most common sites of 
origin is the frontal lobes which is not match with 
other studies in literature ¹³⁻²²⁻²³⁻³²⁻³⁶⁻⁴⁵. None of our 
patients presented with their tumour in 
intraventricular region, although in many series 
reported intraventricular sarcomas which originated 
from the choroid plexus²³⁻²⁶⁻²⁸⁻⁴º⁻⁴¹⁴⁵. A common 
feature of primary CNS sarcoma is dural 
involvement⁵⁻¹⁷⁻³⁶⁻⁴⁴⁻⁴⁵⁻⁴⁷. We have dural 
involvement of the tumour in 3 patients which 
considered as a half of the cases in our study. We did 
not report any malignant glial tumour within or 
adjacent to the primary sarcoma on our series. 
Although some series document that reactive glioma 
can be happened in a primary CNS sarcoma 
¹⁶⁻²³⁻²⁹⁻⁴⁶. 
Primary sarcomas of CNS has the ability to send 
metastasis outside the central nervous system, as 
the liver, bone, and lung with a poor 
prognosis³⁻¹²⁻¹³⁻². It is difficult to determine the 
incidence of the different histological subtypes of 
these tumour. This is due rare incidence of the 
lesion, and the deficient criteria for including specific 
subtypes in the patients who documented in study 
³⁻⁴º. We have frequent changes happened in the 
classification system for primary CNS sarcomas due 
to appearance of new histological subtypes such as 
malignant fibrous histiocytoma, and in the literature 
its considered as most common soft tissue 
sarcoma⁴⁻⁵⁻¹⁶⁻²⁷⁻³⁸ .  
Undifferentiated sarcoma considered as the 
most common pathological type in our study, and 
this not matched with others series ⁷⁻⁴⁵. Other series 
reported fibrosarcomas and MFH as the most 
pathological tumoural subtype ¹⁻²⁻⁹⁻³⁶.  
Primary CNS sarcomas characteristic with a bad 
prognosis, although the long duration of 
postoperative survival is well reported in many series 
in literature¹³⁻³¹⁻³²⁻³⁴⁻⁴º⁻⁴⁵. 
Many studies in the literature reported that gross 
surgical resection is considered as the best 
treatment of choice. We can use postoperative 
radiation or chemotherapy for prolonged the patient 
survival ¹⁻³⁻¹¹⁻¹³⁻¹⁷⁻¹⁶⁻³⁶⁻⁴º⁻⁴⁵⁻⁴⁶.  
In Our study, we found that maximal surgical 
resection of the tumour followed by post-operative 
radiotherapy help the patient to receive his best 
choice of management. Although, There are many 
side effects of radiation on young patient category. 
The aim of postoperative chemotherapy could not 
be exactly reported in our study.  
 
CONCLUSION 
The primary central nervous system sarcoma is a 
rare tumour that mainly originated in the 
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supratentorial region with ability to be exist in the 
intraspinal region. CSF dissemination and dural 
attachment of the tumour are frequently exist. 
Metastases outside the CNS associated with bad 
prognosis. For long term survival we advised gross 
surgical resection followed by postoperative 
radiotherapy. Chemotherapy regimens may be 
considered as one of the factor that prolong the 
survival if they are tolerated by the patient. Future 
studies should be focused to understand the 
histopathological subtypes of primary CNS sarcoma 
to use different chemotherapeutic agents which be 
helpful to give patients long survival and best choice 
of treatment. 
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